Compare C3.ai Inc (AI) vs Boston Scientific Corporation (BSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
C3.ai Inc vs Boston Scientific Corporation — how do they compare? C3.ai Inc trades at $10.49 (market cap $1.65B), while Boston Scientific Corporation trades at $50.98 (market cap $74.19B). The key difference: Boston Scientific Corporation is far larger — about 45× C3.ai Inc's market cap, and C3.ai Inc is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| AI | BSX | |
|---|---|---|
Market Cap | $1.65B | $74.19B |
Sector | Technology | Health |
52-Week High | $19.66 | $108.14 |
52-Week Low | $7.76 | $42.63 |
Enterprise Value | $1.08B | $86.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
C3.ai (AI) trades at $10.40, up 1.76% with a bullish technical signal despite negative profitability metrics. The company reported Q1 2026 earnings beat but maintains negative net margins of -187.95%. Recent news highlights C3.ai being named a leader in AI platforms by Forrester Research, while technical indicators show RSI levels near 90 suggesting overbought conditions.
The stock faces significant fundamental challenges with persistent losses and negative cash flow, though revenue growth and leadership positioning in enterprise AI provide long-term potential. Analyst consensus is mixed with a $10.20 price target, indicating cautious optimism amid execution risks and competitive pressures in the AI software market.
BSX trades at $50.46, up 2.33% today, with strong earnings beats in recent quarters and a bullish technical trend. Revenue grew to $20.07B in 2025, with net income margin expanding to 17.5%. The stock shows robust institutional support and insider buying, while facing near-term headwinds from competitive pressures in key segments like WATCHMAN.
Outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target, implying 33% upside. Risks include guidance cuts and market share losses, but solid cash flow and valuation metrics support long-term growth potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About C3.ai Inc
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →
